Quantum BioPharma Statistics
Total Valuation
QNTM has a market cap or net worth of $9.56 million. The enterprise value is $2.66 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QNTM has 1.92 million shares outstanding. The number of shares has increased by 31.09% in one year.
| Current Share Class | 1.92M |
| Shares Outstanding | 1.92M |
| Shares Change (YoY) | +31.09% |
| Shares Change (QoQ) | +43.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.76, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.76 |
| Quick Ratio | 3.72 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -367.85 |
Financial Efficiency
Return on equity (ROE) is -73.84% and return on invested capital (ROIC) is -46.47%.
| Return on Equity (ROE) | -73.84% |
| Return on Assets (ROA) | -37.73% |
| Return on Capital (ROIC) | -46.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$602,175 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.43% in the last 52 weeks. The beta is 0.85, so QNTM's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -93.43% |
| 50-Day Moving Average | 4.79 |
| 200-Day Moving Average | 20.46 |
| Relative Strength Index (RSI) | 48.17 |
| Average Volume (20 Days) | 87,115 |
Short Selling Information
The latest short interest is 23,918, so 1.25% of the outstanding shares have been sold short.
| Short Interest | 23,918 |
| Short Previous Month | 10,086 |
| Short % of Shares Out | 1.25% |
| Short % of Float | 1.50% |
| Short Ratio (days to cover) | 0.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.46M |
| Pretax Income | n/a |
| Net Income | -10.24M |
| EBITDA | -10.96M |
| EBIT | -11.46M |
| Earnings Per Share (EPS) | -$12.91 |
Full Income StatementBalance Sheet
The company has $6.61 million in cash and $373,024 in debt, giving a net cash position of $6.23 million or $3.25 per share.
| Cash & Cash Equivalents | 6.61M |
| Total Debt | 373,024 |
| Net Cash | 6.23M |
| Net Cash Per Share | $3.25 |
| Equity (Book Value) | 15.35M |
| Book Value Per Share | 8.74 |
| Working Capital | 10.16M |
Full Balance SheetCash Flow
| Operating Cash Flow | -6.89M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.89M |
| FCF Per Share | -$3.59 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |